Naivek, a peptide fusion bio-specialized company, announced on the 27th that it has developed a ‘GRP78-like peptide’ with effects that inhibit and reverse aging and has filed a patent for it. This patent can be applied in various fields such as ▲compositions for reversing human aging ▲new drugs for the prevention and treatment of muscle diseases ▲cosmetics for aging prevention and reversal, and is expected to become a game changer in the global anti-aging market.
This patent relates to peptides and their uses that can restore and regenerate the functions of cells and human tissues related to aging. Naivek previously developed an aging reversal peptide and filed a patent in December last year during the execution of a national project. Compared to the existing patent, they not only added new types of aging reversal peptides but also expanded the patent scope to establish a solid entry barrier for related technologies, leading to the filing of this new patent.
The GRP78-like peptide developed by Naivek showed biomarker patterns similar to those measured in young cells when injected into aging cells. In animal experiments, administration of the GRP78-like peptide to aged mice resulted in decreased expression of aging biomarker indicators, and simultaneously, muscle regeneration and functional recovery were confirmed.
The aging reversal peptide regulates the endoplasmic reticulum (ER) stress response in a manner similar to the GRP78 protein, which controls ER stress, and restores mitochondrial dysfunction. The company explained that through this patent, they have demonstrated the mechanism of the aging reversal peptide to reverse and recover aging in cells, organs, and muscles.
A Naivek representative stated, “This aging reversal patent, based on the ER stress response regulation function of GRP78, can be utilized for various purposes such as related new drugs, cosmetics, and food products. Since the peptide’s aging reversal efficacy has already been verified through animal experiments, we plan to accelerate follow-up research and development with global pharmaceutical companies after establishing a technological entry barrier.”
Advanced countries worldwide, including South Korea, are experiencing rapid social structural changes due to population aging. Health authorities in each country recognize aging as a disease and are focusing their capabilities on developing new technologies to control and reverse it. The World Health Organization (WHO) also included aging as a disease with a disease code in the ‘IDC-11’ disease classification statistics in 2018, recognizing aging as a preventable and treatable disease.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
